SCHEMBL13434848

SCHEMBL13434848

NC(=O)c1ccc(Nc2ncnc3ccsc23)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2C Q8TBX8 1/20 0.61
FLT1 P17948 2/20 0.59
CD38 P28907 2/20 0.53
EGFR P00533 2/20 0.52
FADS1 O60427 1/20 0.52
NTRK1 P04629 6/20 0.52
MKNK1 Q9BUB5 1/20 0.51
AURKA O14965 1/20 0.51
AURKB Q96GD4 1/20 0.51
PRMT1 Q99873 1/20 0.49
F9 P00740 1/20 0.48
PIM1 P11309 2/20 0.47
CSNK2B P67870 1/20 0.47
CSNK2A1 P68400 1/20 0.47
PIM2 Q9P1W9 1/20 0.47
CDC7 O00311 1/20 0.46
ROCK2 O75116 1/20 0.46
MAP4K4 O95819 1/20 0.46
PRKACA P17612 1/20 0.46
CDK2 P24941 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29808582 1.00 PIP4K2C (0.61) PIP4K2CFLT1CD38EGFRFADS1
SCHEMBL24466918 0.85 EGFR (0.64) PIP4K2CFLT1EGFRFADS1NTRK1
SCHEMBL29808690 0.85 EGFR (0.64) PIP4K2CFLT1EGFRFADS1NTRK1
SCHEMBL13434893 0.80 FADS1 (0.58) PIP4K2CFLT1EGFRFADS1NTRK1
SCHEMBL13434857 0.80 PIP4K2C (0.54) PIP4K2CFLT1EGFRFADS1NTRK1
SCHEMBL24467014 0.79 KDR (0.55) FLT1EGFRAURKAAURKBPIM1
SCHEMBL29808512 0.79 KDR (0.55) FLT1EGFRAURKAAURKBPIM1
SCHEMBL5334636 0.78 EGFR (0.55) PIP4K2CFLT1EGFRFADS1NTRK1
SCHEMBL30715841 0.78 EGFR (0.69) PIP4K2CFLT1EGFRFADS1NTRK1
SCHEMBL24466943 0.77 PIP4K2C (0.62) PIP4K2CFLT1CD38EGFRFADS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402935-A1 HETEROCYCLIC COMPOUND FIMECS, INC. (JP) 2022-12-22 US disclosed
EP-4006037-A1 HETEROCYCLIC COMPOUND Fimecs, Inc. (JP) 2022-06-01 EP disclosed
US-8633201-B2 Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-21 US disclosed
US-8633201-B2 Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-21 US disclosed
US-20100056548-A1 THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-03-04 US disclosed
US-20100056548-A1 THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-03-04 US disclosed
WO-2007115822-A1 THIENOPYRIMIDINES HAVING MNKL /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402935-A1 HETEROCYCLIC COMPOUND IRAK1, IRAK2, IRAK4 PIP4K2C 2038/4885FLT1 1577/4885CD38 2317/4885
US-20100056548-A1 THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS CMPK1, DTYMK, NEK9 PIP4K2C 176/4885FLT1 3883/4885CD38 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.